Meme Kanserinde Tarama ve Erken Tanı
Özet
Sağlanan gelişmelerle son 50 yılda meme kanseri mortalitesi azalma gösterse de meme kanseri halen, kadınlarda kansere bağlı ölümlerin en önde gelen nedenlerindendir. Hastalık ileri evrelerde teşhis edildiğinde çok daha mortal seyretmektedir. Bu noktada, etkin tarama stratejileriyle hastalığın erken teşhisi büyük önem taşımaktadır. Ancak her kadında yaşam boyu meme kanseri gelişme riski aynı değildir. Uygun tarama stratejilerinin belirlenmesi; genetik test, kemoprevansiyon ve/veya profilaktik cerrahi gibi müdahale gereken grupların tespit edilmesi için risk grupları iyi tanımlanmalı ve risk temelli etkin tarama programları uygulanmalıdır.
Referanslar
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer Journal for Clinicians. 2024;74(1): 12-49. doi:10.3322/caac.21820
Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. Journal of the National Cancer Institute. 2015;107(6): djv048. doi:10.1093/jnci/djv048
Tabár L, Dean PB, Chen TH, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125(4): 515-523. doi:10.1002/cncr.31840
Nicholson WK, Wong JB, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22): 1918-1930. doi:10.1001/jama.2024.5534
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology. 2007;25(11): 1329-1333. doi:10.1200/JCO.2006.09.1066
Myers ER, Moorman P, Gierisch JM, et al. Benefits and Harms of Breast Cancer Screening: A Systematic Review. JAMA. 2015;314(15): 1615-1634. doi:10.1001/jama.2015.13183
Final recommendation statement: Breast cancer: Screening. US Preventive Services Task Force. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening#bcei-recommendation-title-area (Accessed on Feb 26, 2025).
Nelson HD, Fu R, Cantor A, et al. Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. Annals of Internal Medicine. 2016;164(4): 244-255. doi:10.7326/M15-0969
Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force. JAMA. 2024;331(22): 1947-1960. doi:10.1001/jama.2023.24766
Ministry of Health. Cancer Screenings. Available at: https://hsgm.saglik.gov.tr/tr/kanser-taramalari (Accessed on Feb 26, 2025).
Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer Journal for Clinicians. 2007;57(2): 75-89. doi:10.3322/canjclin.57.2.75
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: Breast and ovarian. 2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bopp.pdf (Accessed on Feb 27, 2025).
